Background:

Extranodal natural killer (NK)/T-cell lymphoma (ENKTL) is a rare aggressive type of non-Hodgkin's lymphoma associated with Epstein-Barr virus infection, it is more prevalent in Asia than in other regions, accounting for ~6% of lymphoma subtypes in China. Relapsed or refractory ENKTL (RR-ENKTL) cases are characterized by a high rate of relapse and dismal prognosis with limited therapeutic options. The median survival in the relapsed/refractory setting is only slightly more than 6 months. Available data from retrospective and prospective studies have shown that high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) improves survival in patients with chemotherapy-sensitive disease, both upfront and salvage therapy. The use of immune checkpoint inhibitors (ICIs), represented by programmed cell death protein 1 (PD-1) antibodies, have produced a unique and significant remission rate in RR-ENKTL from 2018. We have previously reported superior outcomes in patients who received immunotherapy maintenance therapy (immuno-MT) in complete remission (CR). These findings have raised questions about the comparative performance of ASCT vs. immuno-MT in CR patients who experience refractory or relapse. Herein, to further investigate the comparative effectiveness of ASCT vs. immuno-MT in patients with RR-ENKTL.

Method:

We used the database of Sun Yat-sen University Cancer Center (SYSUCC) compare the outcome of patients with RR-ENKTL who failed from asparaginase containing regimens and received ASCT or immuno-MT after attaining a CR (CR2). Patients between ages 18 and 75 with a diagnosis of RR-ENKTL were included if they received ASCT between 2006-2023 or immuno-MT between 2018-2023 while in a CR by CT or PET scan and per the 2014 Lugano definition. Patients undergoing ASCT or immuno-MT with only one prior therapy line in CR (CR1) were excluded. Immuno-MT included PD-1/L1 antibody monotherapy or PD-1 antibody plus chidamide (an oral subtype-selective histone deacetylase inhibitor, HDACi). The primary endpoints of the study were progression-free survival (PFS) and overall survival (OS). PFS was defined as the time from either ASCT or immuno-MT to relapse, progression or death from any cause. OS1 was defined as the time from front-line treatment to death from any cause. OS2 was defined as the time from ASCT or immuno-MT to death from any cause.

Results:

We identified 63 patients with RR-ENKTL who received ASCT (n = 32) or immuno-MT (n = 31) while in a CR2, and key baseline characteristics are shown that, the two groups were balanced for patients' age (median 33.5 vs. 37 years; p = 0.32), female sex (13.6% vs. 15.3%; p = 0.87) and proportion of patients with advanced stage before ASCT or immuno-MT (56.3% vs. 45.2%; p = 0.38). Median lines of therapies before ASCT or immuno-MT were both 2. In the ASCT group, a smaller proportion of patients had PET or PET/CT performed prior to ASCT (68.8% vs. 96.8%; p = 0.003) and no patients were treated with immunotherapy before 2018. Three patients from the immuno-MT group received ASCT and 4 patients from the ASCT group received PD-1 antibody maintenance. As of last follow-up July 1, 2024, median follow-up was 43.6 months for ASCT group and 55.3 months for the immuno-MT group. Median cycles and time of immuno-MT were 17(5-80) cycles and 17.3 months (3-68). Patients who received immuno-MT had a superior PFS (median PFS not reached vs. 39.8 months, p=0.046), OS1 (median OS1 not reached vs. 78.7 months, p=0.023) and OS2 (median OS2 not reached vs. 74.2 months, p=0.031). The OS2 was numerically higher in the year 2018-2023 compared to the year 2006-2017 (median OS2 not reached vs. 74.2 months, p=0.09).

Conclusion:

These results may inform, or validate, clinical practices in select settings. Immunotherapy maintenance strategy alone may lead to improved long-term survival in patients with RR-ENKTL in CR2. Prospective randomized studies to make comparation between ASCT consolidation and immunotherapy maintenance worth exploring.

Disclosures

No relevant conflicts of interest to declare.

This content is only available as a PDF.
2024
Sign in via your Institution